Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 11, 2011, Pages 1036-1041

  Omata, Fumio ^a,b   Shintani, Ayumi ^c   Isozaki, Mitsuhiro ^d   Masuda, Katsunori ^a   Fujita, Yoshiyuki ^a   Fukui, Tsuguya ^a,b  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b St Luke's Life Science Institute   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

colorectal neoplasms; prediction model; quantitative fecal immunochemical test

Indexed keywords

ADENOMA; ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SIZE; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; INTESTINE VILLUS; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADENOMATOUS POLYPS; AGE FACTORS; AGED; BODY MASS INDEX; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; MODELS, STATISTICAL; OCCULT BLOOD; SEX FACTORS;

EID: 80053635192     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834a2882     Document Type: Article

References (20)

1. Kuriki K, Tajima K. The increasing incidence of colorectal cancer and the preventive strategy in Japan. Asian Pac J Cancer Prev 2006; 7:495-501.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-532.
3. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36:2251-2270.
4. Shinya H,Wolff WI. Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg 1979; 190:679-683.
5. Winawer SJ. Colorectal cancer screening comes of age. N Engl J Med 1993; 328:1416-1417. (Pubitemid 23131395)
6. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155-159. (Pubitemid 26017953)
7. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150:162-169.
8. Vilkin A, Rozen P, Levi Z,Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100:2519-2525.
9. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146:244-255. (Pubitemid 351650610)
10. Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010; 116:2115-2125.
11. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105:2017-2025.
12. Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: A meta-analysis. J Dig Dis 2010; 11:148-160.
13. Hosogaya S, Ozaki Y, Naka K. Detection limit, real sensitivity, quantitative limit; how to evaluate detection limit of quantitative method. Medical Technology 2000; 3:221-224.
14. Itzkowitz SH, Potack J. Colonic polyps and polyposis syndromes. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger & fordtran's gastrointestinal and liver disease. 9th ed. Philadelphia: Saunders Elsevier.2010; pp. 2159-2161.
15. Van Roon AH,Wilschut JA, Hol L, Van Ballegooijen M, Reijerink JC, Mannetje H, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011; 9:333-339.
16. Zorzi M, Fedato C, Naldoni C, Sassatelli R, Sassoli De' Bianchi P, Senore C, et al. Screening for colorectal cancer in Italy: 2007 survey. Epidemiol Prev 2009; 33:57-74.
17. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134:1570-1595. (Pubitemid 351615355)
18. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy: The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977-1981. (Pubitemid 24015040)
19. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704-2714. (Pubitemid 39665324)
20. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149:441-450.